These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19104905)

  • 1. PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy.
    Marmolino D; Acquaviva F; Pinelli M; Monticelli A; Castaldo I; Filla A; Cocozza S
    Cerebellum; 2009 Jun; 8(2):98-103. PubMed ID: 19104905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia.
    Rodríguez-Pascau L; Britti E; Calap-Quintana P; Dong YN; Vergara C; Delaspre F; Medina-Carbonero M; Tamarit J; Pallardó FV; Gonzalez-Cabo P; Ros J; Lynch DR; Martinell M; Pizcueta P
    Neurobiol Dis; 2021 Jan; 148():105162. PubMed ID: 33171227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich's ataxia.
    Alfedi G; Luffarelli R; Condò I; Pedini G; Mannucci L; Massaro DS; Benini M; Toschi N; Alaimo G; Panarello L; Pacini L; Fortuni S; Serio D; Malisan F; Testi R; Rufini A
    Mov Disord; 2019 Mar; 34(3):323-334. PubMed ID: 30624801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.
    Marmolino D; Acquaviva F
    Cerebellum; 2009 Sep; 8(3):245-59. PubMed ID: 19165552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model.
    Tomassini B; Arcuri G; Fortuni S; Sandi C; Ezzatizadeh V; Casali C; Condò I; Malisan F; Al-Mahdawi S; Pook M; Testi R
    Hum Mol Genet; 2012 Jul; 21(13):2855-61. PubMed ID: 22447512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Transcriptome Analysis Identifies FXN and BDNF as Novel Targets of miRNAs in Friedreich's Ataxia Patients.
    Misiorek JO; Schreiber AM; Urbanek-Trzeciak MO; Jazurek-Ciesiołka M; Hauser LA; Lynch DR; Napierala JS; Napierala M
    Mol Neurobiol; 2020 Jun; 57(6):2639-2653. PubMed ID: 32291635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia.
    Coppola G; Marmolino D; Lu D; Wang Q; Cnop M; Rai M; Acquaviva F; Cocozza S; Pandolfo M; Geschwind DH
    Hum Mol Genet; 2009 Jul; 18(13):2452-61. PubMed ID: 19376812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia.
    Hayashi G; Shen Y; Pedersen TL; Newman JW; Pook M; Cortopassi G
    Hum Mol Genet; 2014 Dec; 23(25):6838-47. PubMed ID: 25104852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells.
    Vilema-Enríquez G; Quinlan R; Kilfeather P; Mazzone R; Saqlain S; Del Molino Del Barrio I; Donato A; Corda G; Li F; Vedadi M; Németh AH; Brennan PE; Wade-Martins R
    J Biol Chem; 2020 Dec; 295(52):17973-17985. PubMed ID: 33028632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No changes in heme synthesis in human Friedreich´s ataxia erythroid progenitor cells.
    Steinkellner H; Singh HN; Muckenthaler MU; Goldenberg H; Moganty RR; Scheiber-Mojdehkar B; Sturm B
    Gene; 2017 Jul; 621():5-11. PubMed ID: 28412459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis.
    Wong A; Yang J; Cavadini P; Gellera C; Lonnerdal B; Taroni F; Cortopassi G
    Hum Mol Genet; 1999 Mar; 8(3):425-30. PubMed ID: 9949201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurodegeneration in Friedreich's ataxia: from defective frataxin to oxidative stress.
    Gomes CM; Santos R
    Oxid Med Cell Longev; 2013; 2013():487534. PubMed ID: 23936609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia.
    Plasterer HL; Deutsch EC; Belmonte M; Egan E; Lynch DR; Rusche JR
    PLoS One; 2013; 8(5):e63958. PubMed ID: 23691127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
    Libri V; Yandim C; Athanasopoulos S; Loyse N; Natisvili T; Law PP; Chan PK; Mohammad T; Mauri M; Tam KT; Leiper J; Piper S; Ramesh A; Parkinson MH; Huson L; Giunti P; Festenstein R
    Lancet; 2014 Aug; 384(9942):504-13. PubMed ID: 24794816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in the Treatment Strategies of Friedreich's Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms.
    Saini AK; Anil N; Vijay AN; Mangla B; Javed S; Kumar P; Ahsan W
    Curr Pharm Des; 2024; 30(19):1472-1489. PubMed ID: 38638052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich's ataxia.
    Rufini A; Fortuni S; Arcuri G; Condò I; Serio D; Incani O; Malisan F; Ventura N; Testi R
    Hum Mol Genet; 2011 Apr; 20(7):1253-61. PubMed ID: 21216878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting NRF2 for the Treatment of Friedreich's Ataxia: A Comparison among Drugs.
    Petrillo S; D'Amico J; La Rosa P; Bertini ES; Piemonte F
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31640150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frataxin and frataxin deficiency in Friedreich's ataxia.
    Wilson RB
    J Neurol Sci; 2003 Mar; 207(1-2):103-5. PubMed ID: 12614940
    [No Abstract]   [Full Text] [Related]  

  • 19. Frataxin mRNA isoforms in FRDA patients and normal subjects: effect of tocotrienol supplementation.
    Abruzzo PM; Marini M; Bolotta A; Malisardi G; Manfredini S; Ghezzo A; Pini A; Tasco G; Casadio R
    Biomed Res Int; 2013; 2013():276808. PubMed ID: 24175286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA repair pathways are altered in neural cell models of frataxin deficiency.
    Moreno-Lorite J; Pérez-Luz S; Katsu-Jiménez Y; Oberdoerfer D; Díaz-Nido J
    Mol Cell Neurosci; 2021 Mar; 111():103587. PubMed ID: 33418083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.